Literature DB >> 31950201

[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].

David Krug1, Alexander Fabian2, Jürgen Dunst2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31950201     DOI： 10.1007/s00066-019-01574-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment.

Authors:  Terufumi Kawamoto; Naoto Shikama; Keisuke Sasai
Journal:  Radiother Oncol       Date:  2018-10-15       Impact factor: 6.280

2.  Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer.

Authors:  Icro Meattini; Isacco Desideri; Vieri Scotti; Gabriele Simontacchi; Lorenzo Livi
Journal:  Breast       Date:  2018-08-09       Impact factor: 4.380

3.  Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.

Authors:  Sophie Hans; Paul Cottu; Youlia M Kirova
Journal:  Radiother Oncol       Date:  2017-09-27       Impact factor: 6.280

4.  CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.

Authors:  Nicholas B Figura; Thrisha K Potluri; Homan Mohammadi; Daniel E Oliver; John A Arrington; Timothy J Robinson; Arnold B Etame; Nam D Tran; James K Liu; Hatem Soliman; Peter A Forsyth; Solmaz Sahebjam; H Michael Yu; Hyo S Han; Kamran A Ahmed
Journal:  J Neurooncol       Date:  2019-08-09       Impact factor: 4.130

5.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

6.  Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Hannah H Linden; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2019-03-28       Impact factor: 91.245

7.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

8.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

9.  Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.

Authors:  Mudit Chowdhary; Neilayan Sen; Akansha Chowdhary; Lydia Usha; Melody A Cobleigh; Dian Wang; Kirtesh R Patel; Parul N Barry; Ruta D Rao
Journal:  Adv Radiat Oncol       Date:  2019-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.